1. Search Result
Search Result
Results for "

rectifier

" in MCE Product Catalog:

17

Inhibitors & Agonists

1

Dye Reagents

1

Peptides

1

Natural
Products

Cat. No. Product Name Target Research Areas
  • HY-110015
    (-)-Chromanol 293B

    Others Cardiovascular Disease
    (-)-Chromanol 293B is a potent and selective inhibitor of the slow component of delayed rectifier K + current (IKs). (-)-Chromanol 293B can be used for the research of antiarrhythmic.
  • HY-101253
    AM-92016 hydrochloride

    Others Cardiovascular Disease
    AM-92016 hydrochloride is a specific blocker of rectifier potassium current (IK). AM-92016 hydrochloride delays rectifier potassium channel (IK), repolarizes the membrane thereby restricting the duration of the nerve impulse thereby restricting the duration of the nerve impulse.
  • HY-106855
    Almokalant

    H 234​/09

    Potassium Channel Cardiovascular Disease
    Almokalant is a class III antiarrhythmic drug, acts as a potassium channel blocker, and inhibits a specific component (Ikr) of the time-dependent delayed rectifier K + current.
  • HY-N2338
    Cholesterol myristate

    Cholesteryl myristate; Cholesteryl tetradecanoate

    nAChR GABA Receptor Potassium Channel Endogenous Metabolite Cancer
    Cholesterol myristate is a natural steroid present in traditional Chinese medicine. Cholesterol myristate binds to several ion channels such as the nicotinic acetylcholine receptor, GABAA receptor, and the inward-rectifier potassium ion channel.
  • HY-A0148A
    Halofantrine hydrochloride

    SKF-102886; WR-171669 hydrochloride

    Parasite Infection
    Halofantrine hydrochloride (SKF-102886) is a blocker of delayed rectifier potassium current via the inhibition of human-ether-a-go-go-related gene (HERG) channel and a potent antimalarial compound.
  • HY-B0387A
    Ibutilide

    U70226E free base

    Potassium Channel Cardiovascular Disease
    Ibutilide (U70226E free base), an action potential-prolonging antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K + current (IKr) in AT-1 cells.
  • HY-100712
    DPO-1

    Potassium Channel Cardiovascular Disease
    DPO-1 is a potent inhibitor of the voltage-gated potassium channel subtype Kv1.5 and a blocker of ultrarapid delayed rectifier potassium current. DPO-1 prevents atrial arrhythmia.
  • HY-101436A
    Sematilide hydrochloride

    CK-1752 hydrochloride

    Potassium Channel Cardiovascular Disease
    Sematilide hydrochloride (CK-1752 hydrochloride) is a selective IKr channel blocker. Sematilide causes a concentration-dependent inhibition of the delayed rectifier K + current (IC50=25 μM). Sematilide is a class III antiarrhythmic agent.
  • HY-101436
    Sematilide

    CK-1752

    Potassium Channel Cardiovascular Disease
    Sematilide (CK-1752) is a selective IKr channel blocker. Sematilide causes a concentration-dependent inhibition of the delayed rectifier K + current (IC50=25 μM). Sematilide is a class III antiarrhythmic agent.
  • HY-108575
    Chromanol 293B

    Potassium Channel CFTR Cardiovascular Disease
    Chromanol 293B is a selective blocker of the slow delayed rectifier K + current (IKs) with IC50 of 1-10 μM and a weak inhibitor of KATP channel. Chromanol 293B also blocks the CFTR chloride current with an IC50 of 19 μM.
  • HY-P1427
    Guangxitoxin 1E

    Potassium Channel Neurological Disease
    Guangxitoxin 1E is a potent and selective blocker of KV2.1 and KV2.2 channels. Guangxitoxin 1E inhibits KV2 with an IC50 of 1-3 nM. KV2 channels underlie delayed-rectifier potassium currents in various neurons.
  • HY-16915
    RPR-260243

    Potassium Channel Cardiovascular Disease
    RPR-260243, a potent activator of human ether-a-go-go-related gene (hERG), slows deactivation and attenuates inactivation of hERG1 channels. RPR260243-modified HERG currents are inhibited by Dofetilide (IC50=58 nM). RPR260243 displays no activator-like effects on other voltage-dependent ion channels, including the closely related ERG3 K+ channel.
  • HY-B0883
    Proflavine hemisulfate

    Proflavin hemisulfate; 3,6-Diaminoacridine hemisulfate

    Bacterial Potassium Channel Autophagy Infection
    Proflavine hemisulfate, an acridine dye, is a known DNA intercalating agent. Anti-microbial agent. Proflavine hemisulfate behaves as a pore blocker for Kir3.2. Proflavine hemisulfate is a potential lead compound for Kir3.2-associated neurological diseases.
  • HY-B1741
    Proflavine

    3,6-Diaminoacridine

    Bacterial Neurological Disease
    Proflavine, an acridine dye, is a known DNA intercalating agent. Anti-microbial agent. Proflavine behaves as a pore blocker for Kir3.2. Proflavine is a potential lead compound for Kir3.2-associated neurological diseases.
  • HY-B0432
    Propafenone

    SA-79

    Sodium Channel Adrenergic Receptor Potassium Channel Cancer Cardiovascular Disease
    Propafenone (SA-79), a sodium-channel blocker, acts an antiarrhythmic agent. Propafenone also has high affinity for the β receptor (IC50=32 nM). Propafenone blocks the transient outward current (Ito) and the sustained delayed rectifier K current (Isus) with IC50 values of 4.9 μm and 8.6 μm, respectively. Propafenone suppresses esophageal cancer proliferation through inducing mitochondrial dysfunction and induce apoptosis.
  • HY-118607
    VU041

    Potassium Channel Parasite Infection
    VU041 is a first submicromolar-affinity inhibitor of Anopheles (An.) gambiae and Aedes (Ae.) aegypti inward rectifier potassium 1 (Kir1) channels with IC50 values of 2.5 μM and 1.7 μM, respectively. VU041 inhibits appreciably is mammalian Kir2.1 (IC50 of 12.7 μM), and has less inhibitory effect on mammalian Kir1.1, Kir4.1, Kir6.2/SUR1, and Kir7.1. VU041 also induces impaired Malpighian tubule function.
  • HY-112544
    IK1 inhibitor PA-6

    PA-6

    Potassium Channel Cardiovascular Disease
    IK1 inhibitor PA-6 (PA-6), a pentamidine analogue, is a selective and potent IK1 (KIR2.x ion-channel-carried inward rectifier current) inhibitor, with IC50 values of 12-15 nM for human and mouse KIR2.x currents. IK1 inhibitor PA-6 (PA-6) elevates KIR2.1 protein expression and induces intracellular KIR2.1 accumulation. IK1 inhibitor PA-6 (PA-6) has the potential to treat atrial fibrillation and arrhythmia.